Loading…
Corteva, Inc.
S&P 500
🏹 Trader: 🎯 Near 52W High | BRS 66 Forming View all →
$55.6B
Market Cap
41.9
P/E
1.63
PEG
7.6%
ROCE
5.0%
ROE
0.11
D/E
14.0%
OPM
-8.4%
% from 52W High
56
α RS
🔍 CTVA is showing a sector-leadership setup because Sector RRG has Materials in the Leading quadrant with the trail still strengthening, it matches 2 of 37 tracked screener presets, and an ECS of 69.1 last quarter. Net: Broad signal stack, not a recommendation. ? RRG Conviction ECS
Sources
Materials in Leading quadrant · Conviction 2/37 · ECS 69.1
⚖️ Compare 🔒 Generate Report 🔒 Research Packet 📚 Guides
🌏 Global Investor Returns
Currency-adjusted total returns for CTVA including FX impact
🌏
Click 🌏 Returns tab to load data
📈 Price History
Ratio Health
Excellent
Good
Average
Poor
By Category
📊 Sector Averages
About

Corteva, Inc. operates in the agriculture business.

Key Ratios Snapshot
📈 Growth Pattern
📊 Quick Scorecard
Loading…
⭐ Superinvestors Holding CTVA
View All Superinvestors →
Manager Shares Value % of Fund Period
Steve Cohen Point72 Asset Management 22.9K $1.9M 0.00% Mar 2026
Jim Simons Renaissance Technologies LLC 14.6K $1.2M 0.00% Mar 2026

SEC Form 13F data. 45-day lag from quarter end.

🔒
Premium Feature
AI-generated 10-section company profile — business model, financials, strengths, risks & management quality
Upgrade to Premium
Already a member? Log in
📐
3-Statement Financial Model
Bear / Base / Bull projections · DCF fair value · Reverse-DCF
Open Model →
🎙 Management Tone Confident Specific → Stable 5 quarters Full tone analysis in Intelligence →
Good quarter Investor Presentation One-Pager? Q2 2026
Revenue
$6.38B
-1% YoY
Operating EBITDA
$2.26B
+4% YoY
Operating Margin
32.8%
+1.9pp YoY (1H26)
Net Income
$1.22B
-12% YoY
What Went Right
  • First-half operating EBITDA up 10% to $3.70B; margin expanded ~200bps to 32.8%.
  • Seed licensing business is three years ahead of plan; organic seed sales grew in every region in 1H.
  • Crop Protection new products on track to reach ~$2B revenue this year with high-single-digit volume growth.
What to Watch
  • Crop Protection price declined ~3% in 1H; 2H guide assumes low-to-mid-single-digit price decline, led by Brazil.
  • Full-year net dis-synergies, tariffs and Middle East conflict costs hit 2H; EBITDA expected flat YoY.
  • Brazilian farmer credit is tight; fuel and fertilizer costs are pressuring grower margins and order timing.
Management Guidance
  • FY26 Operating EBITDA raised to $4.1–$4.3B.
  • FY26 Operating EPS raised to $3.60–$3.80.
  • FY26 Operating EBITDA margin guided at 22.5%–23.5%.
  • 2H EBITDA roughly flat YoY; Q3 operating loss around $100M.
Investor Lens
The thesis looks stronger after this call: management raised full-year guidance on a strong first half, driven by productivity, licensing, and new-product momentum. However, persistent Crop Protection price deflation—mainly in Brazil—and a flat second-half EBITDA outlook keep near-term expectations in check. The September Investor Day will be critical to map out 2029 targets for both New Corteva and Vylor.
From investor presentation · AI-generated analysis · Not investment advice
🔒
Premium Feature
Investor Presentation One-Pager — quarterly highlights, what went right/wrong & management guidance
Upgrade to Premium
Already a member? Log in
📈 STRONG Q2 EBITDA up 4% to $2.26B; FY guidance raised.
Revenue
Q2 net sales were $6.38B, down 1% YoY (organic -2%), while first-half net sales rose 4% to $11.28B. Seed led with 4% growth; Crop Protection was flat organically on 2% volume growth offset by a 3% price decline.
Profitability
Q2 GAAP net income was $1.22B, down 12% YoY, but operating EPS rose 5% to $2.30. First-half operating EPS increased 14% to $3.80.
Margins
First-half operating EBITDA margin expanded to 32.8%, up ~200bps, aided by productivity gains and lower input costs. Pricing pressure in Crop Protection was more than offset by value-capture in Seed and disciplined cost management.
Balance Sheet
First-half free cash flow was impacted by a $1.1B pension contribution, the Bayer Agreement, and one-time separation costs; absent these, full-year FCF conversion would be in the 45–50% target range. Debt and capex details were not discussed.
Key Risks
Management flagged continued Crop Protection price deflation, mostly in Brazil pre-emergent herbicides, a flat second-half EBITDA versus a strong prior-year half, and tight credit conditions for Brazilian farmers.
Outlook
FY26 Operating EBITDA is now guided to $4.1–$4.3B and Operating EPS to $3.60–$3.80. Second-half EBITDA is expected about flat YoY, with a Q3 operating loss near $100M.
Generated by AI · Q2 2026 results · Not investment advice
🔒
Free Account Required

Create a free Finmagine account to access Finmagine™ Scorecard.

See how this company scores across 5 dimensions — Financial Health, Growth Prospects, Competitive Position, Management Quality, and Valuation — powered by 30+ computed ratios.

Create Free AccountLog In
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Ask AI.

Get 25 expert AI analysis templates — Business KPIs, Comprehensive, Forensic Governance, Peer Comparison, Risk-Reward, Full Research Report, IPO Decoder, Red Flag Detector, and more — ready to paste into ChatGPT, Claude, Gemini, or Perplexity.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Peer Comparison.

Compare this company side-by-side against its sector peers with financial metrics, ratio benchmarking, and relative performance across all key dimensions.

Upgrade to PremiumCreate Free Account
✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter
🔍
🔎 See cross-company document search → ?
📞 Earnings Call Transcripts (5)
Q2 2026 Q2 2026 2026-07-31
Strong first-half 2026 results with 4% sales and 10% EBITDA growth led to raised full-year guidance. Both seed and crop protection segments showed resilience, with margin expansion and robust technology adoption. Separation into two companies remains on track for October 1.
Q1 2026 Q1 2026 2026-05-06
Q1 2026 saw 21% EBITDA growth and margin expansion, driven by strong Seed and Crop Protection performance. Full-year guidance is reaffirmed, with continued organic growth, cost productivity, and progress on the planned separation into two companies.
Q4 2025 Q4 2025 2026-02-04
Delivered strong 2025 results with double-digit EBITDA growth, margin expansion, and robust free cash flow. 2026 guidance calls for 7% EBITDA growth, margin gains, and accelerated royalty neutrality following a major Bayer agreement, despite ongoing pricing and tariff headwinds.
Q3 2025 Q3 2025 2025-11-05
Strong Q3 and year-to-date results led to raised 2025 guidance, with double-digit EBITDA growth, margin expansion, and robust free cash flow. The planned separation into two public companies is on track, with both seed and crop protection segments showing innovation and market leadership.
Q2 2025 Q2 2025 2025-08-07
Q2 and H1 2025 saw strong sales, margin expansion, and cost improvements, leading to raised full-year guidance for EBITDA, EPS, and free cash flow. Seed and crop protection segments both delivered double-digit EBITDA growth, with robust share gains and new product momentum.
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Catalyst Timeline.

Every result, order win, insider trade, ECS update, earnings-call, and SEC announcement for this company — in one chronological lane.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Full Report.

Read the complete Finmagine™ investment research report — comprehensive fundamental analysis, business model assessment, competitive positioning, and investment recommendation.

Upgrade to PremiumCreate Free Account

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯
Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.
📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

Financial Model
Projections are built from each company's audited annual financials (Income Statement, Balance Sheet, Cash Flow) over the last 5 fiscal years. Forward assumptions — revenue growth %, EBITDA margin, D&A (USD millions), interest expense, tax rate, and capex — are AI-generated using historical context and refreshed twice a year: after the December results season and after the September/Q4 results season.

DCF Valuation
Fair Value = Σ(FCFt / (1+WACC)t) + Terminal Value. Terminal Value uses the Gordon Growth Model: FCF5 × (1+g) / (WACC−g). Default WACC: 10% (US risk-free ~4.5%, equity risk premium ~5.5%). Default terminal growth: 3% (long-run US nominal GDP proxy).

CAGR Tracker
Expected 5-year CAGR = (DCF Fair Value / Current Price)1/5 − 1. Assumes fair value is reached in exactly 5 years — a mechanical estimate only.

Data Sources & Limitations
Financial statements sourced from public filings. Prices updated daily. Forward assumptions are AI-generated. All monetary values in USD millions. Non-US ADR companies may have currency conversion inaccuracies. Models are point-in-time and do not update intra-quarter or account for M&A, macro shocks, or extraordinary items.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.